Chronic Infusion of Astaxanthin Into Hypothalamic Paraventricular Nucleus Modulates Cytokines and Attenuates the Renin-Angiotensin System in Spontaneously Hypertensive Rats.
Animals
Anti-Inflammatory Agents
/ administration & dosage
Antihypertensive Agents
/ administration & dosage
Arterial Pressure
/ drug effects
Cytokines
/ metabolism
Disease Models, Animal
Hypertension
/ drug therapy
Inflammation Mediators
/ metabolism
Infusions, Parenteral
Male
Paraventricular Hypothalamic Nucleus
/ drug effects
Rats, Inbred SHR
Rats, Inbred WKY
Renin-Angiotensin System
/ drug effects
Time Factors
Xanthophylls
/ administration & dosage
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
received:
09
04
2020
accepted:
28
10
2020
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Oxidative stress, the renin-angiotensin system (RAS), and inflammation are some of the mechanisms involved in the pathogenesis of hypertension. The aim of this study is to examine the protective effect of the chronic administration of astaxanthin, which is extracted from the shell of crabs and shrimps, into hypothalamic paraventricular nucleus (PVN) in spontaneously hypertensive rats. Animals were randomly assigned to 2 groups and treated with bilateral PVN infusion of astaxanthin or vehicle (artificial cerebrospinal fluid) through osmotic minipumps (Alzet Osmotic Pumps, Model 2004, 0.25 μL/h) for 4 weeks. Spontaneously hypertensive rats had higher mean arterial pressure and plasma level of norepinephrine and proinflammatory cytokine; higher PVN levels of reactive oxygen species, NOX2, NOX4, IL-1β, IL-6, ACE, and AT1-R; and lower PVN levels of IL-10 and Cu/Zn SOD, Mn SOD, ACE2, and Mas receptors than Wistar-Kyoto rats. Our data showed that chronic administration of astaxanthin into PVN attenuated the overexpression of reactive oxygen species, NOX2, NOX4, inflammatory cytokines, and components of RAS within the PVN and suppressed hypertension. The present results revealed that astaxanthin played a role in the brain. Our findings demonstrated that astaxanthin had protective effect on hypertension by improving the balance between inflammatory cytokines and components of RAS.
Identifiants
pubmed: 33538532
doi: 10.1097/FJC.0000000000000953
pii: 00005344-202102000-00008
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antihypertensive Agents
0
Cytokines
0
Inflammation Mediators
0
Xanthophylls
0
astaxanthine
8XPW32PR7I
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
170-181Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Patel P, Ordunez P, DiPette D, et al. Improved blood pressure control to reduce cardiovascular disease morbidity and mortality: the standardized hypertension treatment and prevention project. J Clin Hypertens. 2016;18:1284–1294.
Mittal BV, Singh AK. Hypertension in the developing world: challenges and opportunities. Am J Kidney Dis. 2010;55:590–598.
Campbell NRC, Chen GM. Canadian efforts to prevent and control hypertension. Can J Cardiol. 2010(suppl C):14C–17C.
Huber MJ, Fan Y, Jiang E, et al. Increased activity of the orexin system in the paraventricular nucleus contributes to salt-sensitive hypertension. Am J Physiol Heart Circ Physiol. 2017;313:H1075–H1086.
Tian H, Kang YM, Gao HL, et al. Chronic infusion of berberine into the hypothalamic paraventricular nucleus attenuates hypertension and sympathoexcitation via the ROS/Erk1/2/iNOS pathway. Phytomedicine 2019;52:216–224.
Bai J, Yu XJ, Liu KL, et al. Central administration of tert-butylhydroquinone attenuates hypertension via regulating Nrf2 signaling in the hypothalamic paraventricular nucleus of hypertensive rats. Toxicol Appl Pharmacol. 2017;333:100–109.
Dange RB, Agarwal D, Teruyama R, et al. Toll-like receptor 4 inhibition within the paraventricular nucleus attenuates blood pressure and inflammatory response in a genetic model of hypertension. J Neuroinflammation 2015;12. doi: 10.1186/s12974-015-0242-7.
doi: 10.1186/s12974-015-0242-7
Kang YM, Zhang DM, Yu XJ, et al. Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines. Toxicol Appl Pharmacol. 2014;274:436–444.
Su Q, Qin DN, Wang FX, et al. Inhibition of reactive oxygen species in hypothalamic paraventricular nucleus attenuates the renin-angiotensin system and proinflammatory cytokines in hypertension. Toxicol Appl Pharmacol. 2014;276:115–120.
Yu XJ, Zhang DM, Jia LL, et al. Inhibition of NF-kappa B activity in the hypothalamic paraventricular nucleus attenuates hypertension and cardiac hypertrophy by modulating cytokines and attenuating oxidative stress. Toxicol Appl Pharmacol. 2015a;284:315–322.
Zhang M, Qin DN, Suo YP, et al. Endogenous hydrogen peroxide in the hypothalamic paraventricular nucleus regulates neurohormonal excitation in high salt-induced hypertension. Toxicol Lett. 2015;235:206–215.
Song XA, Jia LL, Cui W, et al. Inhibition of TNF-alpha in hypothalamic paraventricular nucleus attenuates hypertension and cardiac hypertrophy by inhibiting neurohormonal excitation in spontaneously hypertensive rats. Toxicol Appl Pharmacol. 2014;281:101–108.
Yi QY, Li HB, Qi J, et al. Chronic infusion of epigallocatechin-3-O-gallate into the hypothalamic paraventricular nucleus attenuates hypertension and sympathoexcitation by restoring neurotransmitters and cytokines. Toxicol Lett. 2016;262:105–113.
Souza LAC, Worker CJ, Li WC, et al. Am J Physiol Heart Circ Physiol. 2019;316:H1389–H1405. 10.1152/ajpheart.00780.2018.
doi: 10.1152/ajpheart.00780.2018
Niizawa I, Espinaco BY, Zorrilla SE, et al. Natural astaxanthin encapsulation: Use of response surface methodology for the design of alginate beads. Int J Biol Macromol. 2019;121:601–608.
Hussein G, Nakamura M, Zhao Q, et al. Antihypertensive and neuroprotective effects of astaxanthin in experimental animals. Biol Pharm Bull. 2005;28:47–52.
Monroy-Ruiz J, Sevilla MA, Carron R, et al. Astaxanthin-enriched-diet reduces blood pressure and improves cardiovascular parameters in spontaneously hypertensive rats. Pharmacol Res. 2011;63:44–50.
Leif Percival Andersen 1, Holck S, Kupcinskas L, Kiudelis G, et al. Gastric inflammatory markers and interleukins in patients with functional dyspepsia treated with astaxanthin. FEMS Immunol Med Microbiol. 2007;50:244–248.
Qi J, Yu XJ, Fu LY, et al. Exercise training attenuates hypertension through TLR4/MyD88/NF-kappaB signaling in the hypothalamic paraventricular nucleus. Front Neurosci. 2019;13:1138.
Li HB, Li X, Huo CJ, et al. TLR4/MyD88/NF-kappa B signaling and PPAR-gamma within the paraventricular nucleus are involved in the effects of telmisartan in hypertension. Toxicol Appl Pharmacol. 2016;305:93–102.
Palkovits M. Isolated removal of hypothalamic or other brain nuclei of rat. Brain Res. 1973;59:449–450.
Miller FJ, Gutterman DD, Rios CD, et al. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res. 1998;82:1298–1305.
Kang YM, Ma Y, Elks C, et al. Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-kappa B. Cardiovasc Res. 2008;79:671–678.
Su Q, Liu JJ, Cui W, et al. Alpha lipoic acid supplementation attenuates reactive oxygen species in hypothalamic paraventricular nucleus and sympathoexcitation in high salt-induced hypertension. Toxicol Lett. 2016;241:152–158.
Qi J, Zhao XF, Yu XJ, et al. Targeting interleukin-1 beta to suppress sympathoexcitation in hypothalamic paraventricular nucleus in dahl salt-sensitive hypertensive rats. Cardiovasc Toxicol. 2016;16:298–306.
Li HB, Qin DN, Cheng K, et al. Central blockade of salusin beta attenuates hypertension and hypothalamic inflammation in spontaneously hypertensive rats. Sci Rep. 2015;5. doi:10.1097/FJC.0000000000000953.
doi: 10.1097/FJC.0000000000000953
Li HB, Yang T, Richards EM, et al. Maternal treatment with captopril persistently alters gut-brain communication and attenuates hypertension of male offspring. Hypertension. 2020;75:1315–1324.
Xue BJ, Beltz TG, Johnson RF, et al. PVN adenovirus-siRNA injections silencing either NOX2 or NOX4 attenuate aldosterone/NaCl-induced hypertension in mice. Am J Physiol Heart Circ Physiol. 2012;302:H733–H741.
Xue XL, Han XD, Li Y, et al. Astaxanthin attenuates total body irradiation-induced hematopoietic system injury in mice via inhibition of oxidative stress and apoptosis. Stem Cell Res Ther. 2017;8. doi: 10.1097/FJC.0000000000000953.
doi: 10.1097/FJC.0000000000000953
Zheng D, Li Y, He L, et al. The protective effect of astaxanthin on fetal alcohol spectrum disorder in mice. Neuropharmacology 2014;84:13–18.
Zuluaga M, Gueguen V, Letourneur D, et al. Astaxanthin-antioxidant impact on excessive Reactive Oxygen Species generation induced by ischemia and reperfusion injury. Chem Biol Interact. 2018;279:145–158.
Zhang XS, Zhang X, Wu Q, et al. Astaxanthin offers neuroprotection and reduces neuroinflammation in experimental subarachnoid hemorrhage. J Surg Res. 2014;192:206–213.
Zhang XS, Zhang X, Zhang QR, et al. Astaxanthin reduces matrix metalloproteinase-9 expression and activity in the brain after experimental subarachnoid hemorrhage in rats. Brain Res. 2015;1624:113–124.
Ye QY, Zhang XD, Huang BX, et al. Astaxanthin suppresses MPP+-Induced oxidative damage in PC12 cells through a sp1/NR1 signaling pathway. Mar Drugs. 2013;11:1019–1034.
Tsounis D, Bouras G, Giannopoulos G, et al. Inflammation markers in essential hypertension. Med Chem. 2014;10:672–681.
Lin KH, Lin KC, Lu WJ, et al. Astaxanthin, a carotenoid, stimulates immune responses by enhancing IFN-gamma and IL-2 secretion in primary cultured lymphocytes in vitro and ex vivo. Int J Mol Sci. 2016;17. doi: 10.1097/FJC.0000000000000953.
doi: 10.1097/FJC.0000000000000953
Balietti M, Giannubilo SR, Giorgetti B, et al. The effect of astaxanthin on the aging rat brain: gender-related differences in modulating inflammation (vol 96, pg 615, 2015). J Sci Food Agric. 2016;96:4295.
de Morais SDB, Shanks J, Zucker IH. Integrative physiological aspects of brain RAS in hypertension. Curr Hypertens Rep. 2018;20. doi: 10.1097/FJC.0000000000000953.
doi: 10.1097/FJC.0000000000000953
Kang YM, Ma Y, Zheng JP, et al. Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension. Cardiovasc Res. 2009;82:503–512.
Shi P, Diez-Freire C, Jun JY, et al. Brain microglial cytokines in neurogenic hypertension. Hypertension. 2010;56:297–303.
Sriramula S, Cardinale JP, Lazartigues E, et al. ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc Res. 2011;92:401–408.
Zubcevic J, Waki H, Raizada MK, et al. Autonomic-immunevascular interaction: an emerging concept for neurogenic hypertension. Hypertension. 2011;57:1026–1033.
Sriramula S, Cardinale JP, Francis J. Inhibition of TNF in the brain reverses alterations in RAS components and attenuates angiotensin II-induced hypertension. PLoS One. 2013;8:e63847.
Sasamura H, Nakazato Y, Hayashida T, et al. Regulation of vascular type 1 angiotensin receptors by cytokines. Hypertension. 1997;30:35–41.
Arenas IA, Xu Y, Lopez-Jaramillo P, et al. Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol. 2004;286:C779–C784.
Sriramula S, Haque M, Majid DS, et al. Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension. 2008;51:1345–1351.
Coombes JS, Sharman JE, Fassett RG. Astaxanthin has no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients: a randomized controlled trial (the XANTHIN trial). Am J Clin Nutr. 2016;103:283–289.